Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 27, 2013, Pages 11199-11204

  Sprowl, Jason A ^a   Ciarimboli, Giuliano ^b   Lancaster, Cynthia S ^a   Giovinazzo, Hugh ^a   Gibson, Alice A ^a   Du, Guoqing ^a   Janke, Laura J ^a   Cavaletti, Guido ^c   Shields, Anthony F ^d   Sparreboom, Alex ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d WAYNE STATE UNIVERSITY   (United States)

Author keywords

Chemotherapy; Neuropathy; Solute carriers

Indexed keywords

CIMETIDINE; DNA; OCTAMER TRANSCRIPTION FACTOR 2; OXALIPLATIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; COLD SENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG INDUCED DISEASE; FEMALE; HUMAN; HUMAN CELL; MALE; MECHANICAL STIMULATION; MOUSE; NEUROTOXICITY; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPINAL GANGLION;

CHEMOTHERAPY; NEUROPATHY; SOLUTE CARRIERS;

ANIMALS; ANTINEOPLASTIC AGENTS; FEMALE; GANGLIA, SPINAL; HUMANS; MALE; MICE; MICE, KNOCKOUT; NEUROTOXICITY SYNDROMES; OCTAMER TRANSCRIPTION FACTOR-1; ORGANIC CATION TRANSPORT PROTEINS; ORGANOPLATINUM COMPOUNDS;

MUS;

EID: 84879697635     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1305321110     Document Type: Article

References (29)

1. McWhinney SR, Goldberg RM, McLeod HL (2009) Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther 8(1):10-16.
2. Cascinu S, et al. (2002) Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: A randomized, double-blind, placebo-controlled trial. J Clin Oncol 20(16):3478-3483.
3. Gamelin L, et al. (2004) Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: A retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 10(12 Pt 1):4055-4061. (Pubitemid 38812481)
4. Ishibashi K, Okada N, Miyazaki T, Sano M, Ishida H (2010) Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: A prospective randomized study. Int J Clin Oncol 15(1):82-87.
5. Hochster HS, Grothey A, Childs BH (2007) Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J Clin Oncol 25(25):4028-4029. (Pubitemid 47477294)
6. Dong M, Xing PY, Liu P, Feng FY, Shi YK (2010) [Assessment of the protective effect of calcium-magnesium infusion and glutathione on oxaliplatin-induced neurotoxicity]. Zhonghua Zhong Liu Za Zhi 32(3):208-211.
7. Park SB, et al. (2009) Oxaliplatin-induced neurotoxicity: Changes in axonal excitability precede development of neuropathy. Brain 132(Pt 10):2712-2723.
8. Park SB, et al. (2009) Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J Clin Oncol 27(8):1243-1249.
9. Park SB, et al. (2011) Dose effects of oxaliplatin on persistent and transient Na+ conductances and the development of neurotoxicity. PLoS ONE 6(4):e18469.
10. McDonald ES, Randon KR, Knight A, Windebank AJ (2005) Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: A potential mechanism for neurotoxicity. Neurobiol Dis 18(2):305-313. (Pubitemid 40431114)
11. Screnci D, et al. (2000) Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs. Br J Cancer 82(4):966-972. (Pubitemid 30085253)
12. Holmes J, et al. (1998) Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model. Toxicol Sci 46(2):342-351. (Pubitemid 29069619)
13. Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A (2009) Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther 86(4):396-402.
14. Yokoo S, et al. (2007) Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem Pharmacol 74(3):477-487. (Pubitemid 46963232)
15. Buss I, Kalayda GV, Marques-Gallego P, Reedijk J, Jaehde U (2009) Influence of the hOCT2 inhibitor cimetidine on the cellular accumulation and cytotoxicity of oxaliplatin. Int J Clin Pharmacol Ther 47(1):51-54.
16. Filipski KK, Loos WJ, Verweij J, Sparreboom A (2008) Interaction of Cisplatin with the human organic cation transporter 2. Clin Cancer Res 14(12):3875-3880.
17. Franke RM, et al. (2010) Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary N-acetyl-beta-D-glucosaminidase. Clin Cancer Res 16(16):4198-4206.
18. Burger H, et al. (2010) Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2). Br J Pharmacol 159(4):898-908.
19. Katsuda H, et al. (2010) Protecting cisplatin-induced nephrotoxicity with cimetidine does not affect antitumor activity. Biol Pharm Bull 33(11):1867-1871.
20. Graham MA, et al. (2000) Clinical pharmacokinetics of oxaliplatin: A critical review. Clin Cancer Res 6(4):1205-1218. (Pubitemid 30226200)
21. Ta LE, Low PA, Windebank AJ (2009) Mice with cisplatin and oxaliplatin-induced painful neuropathy develop distinct early responses to thermal stimuli. Mol Pain 5:9.
22. Renn CL, et al. (2011) Multimodal assessment of painful peripheral neuropathy induced by chronic oxaliplatin-based chemotherapy in mice. Mol Pain 7:29.
23. Sakurai M, et al. (2009) Oxaliplatin-induced neuropathy in the rat: Involvement of oxalate in cold hyperalgesia but not mechanical allodynia. Pain 147(1-3):165-174.
24. Melisi D, et al. (2009) Oral poly(ADP-ribose) polymerase-1 inhibitor BSI-401 has antitumor activity and synergizes with oxaliplatin against pancreatic cancer, preventing acute neurotoxicity. Clin Cancer Res 15(20):6367-6377.
25. Theile D, Grebhardt S, Haefeli WE, Weiss J (2009) Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy. Biochem Pharmacol 78(11):1366- 1373.
26. Jong NN, Nakanishi T, Liu JJ, Tamai I, McKeage MJ (2011) Oxaliplatin transport mediated by organic cation/carnitine transporters OCTN1 and OCTN2 in overexpressing human embryonic kidney 293 cells and rat dorsal root ganglion neurons. J Pharmacol Exp Ther 338(2):537-547.
27. Ip V, Liu JJ, Mercer JF, McKeage MJ (2010) Differential expression of ATP7A, ATP7B and CTR1 in adult rat dorsal root ganglion tissue. Mol Pain 6:53.
28. Liu JJ, et al. (2009) Neuronal expression of copper transporter 1 in rat dorsal root ganglia: Association with platinum neurotoxicity. Cancer Chemother Pharmacol 64(4):847-856.
29. Ciarimboli G, et al. (2010) Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am J Pathol 176(3):1169-1180.